Viridian Therapeutics (VRDN) stock jumped 20.7% on Monday after the company reported positive results in a clinical trial for its treatment of thyroid eye disease, a condition that causes eye swelling.
The trial showed significant improvements in patients who received Viridian’s veligrotug, with 56% experiencing an improvement in proptosis (eye swelling) and 32% achieving complete resolution. In contrast, only 8% of placebo patients saw similar improvements. The results also demonstrated a benefit for diplopia (double vision), with 56% of Veligrotug recipients showing improvement and 32% experiencing complete resolution.
Analysts note that Viridian’s treatment outperformed Amgen’s Tepezza in key areas, including safety. Specifically, fewer patients experienced hearing problems while on veligrotug compared to Tepezza. This sets Veligrotug apart from its competitors, making it an attractive option for patients with chronic thyroid eye disease.
The positive results have led analysts to upgrade their expectations for Viridian Therapeutics shares. The stock now trades below its 50-day moving average but has the potential to break above this key level in the near future.
Source: https://www.investors.com/news/technology/viridian-therapeutics-chronic-thyroid-eye-diease-amgen-tepezza